Reimagine Care has announced a significant upgrade to Remi, its AI-powered virtual assistant for cancer patients, incorporating large language models to enable more natural patient conversations, expanded safety protections, and new support for patients undergoing advanced therapies such as CAR-T outside the hospital setting.
HotSpot Take
Reimagine Care is expanding its AI-driven virtual oncology platform beyond symptom management into CAR-T and advanced therapy monitoring — a signal that between-visit cancer care is becoming infrastructure, not a supplement.
From Scripts to Conversations: How Remi Has Evolved
AI-powered virtual assistants are extending oncology care beyond clinic walls, giving patients a direct line to their care teams between appointments.
The core shift in this platform evolution is a move from structured, rule-based interactions to AI-driven natural language understanding. According to the company, Remi can now interpret patient intent and context in complex messages, including when patients report multiple symptoms simultaneously, and translate those into structured, clinically meaningful insights that route patients through appropriate care pathways.
Reimagine Care positions the upgrade as addressing a fundamental gap in how patients communicate about their health. Most cancer patients don’t describe symptoms in clinical terms. They describe how they feel, often imprecisely, while managing fear, fatigue, and the side effects of treatment. Earlier chatbot systems built on rigid scripts frequently struggled to capture that nuance.
The platform retains Remi’s SMS-based delivery model, which requires no app download or patient portal login. According to the company, this frictionless approach is intentional, keeping barriers to engagement low for patients across age groups, technology comfort levels, and geographic circumstances.
Oncology-Native Design at the Core
Reimagine Care’s platform differentiation centers on what it describes as “oncology-native design,” meaning the system was built specifically around cancer treatment journeys, symptom patterns, and clinical workflows, rather than adapted from a general-purpose conversational AI tool.
The upgraded Remi includes expanded safety protections: structured prompts, purpose-built monitoring tooling, and continuous automated oversight of patient conversations. The company states that each interaction is evaluated using a proprietary framework designed to keep the system within defined clinical guardrails, with escalation pathways to human clinicians when needed.
On the care team side, the Virtual Care Center interface has been redesigned to support faster clinician response. AI-assisted summarization of patient conversations helps clinicians quickly assess patient needs and prioritize follow-up; a meaningful workflow improvement when managing high volumes of patients between clinic visits.
The Clinical Problem Remi Is Designed to Solve
The upgrade comes against a backdrop of well-documented strain in oncology care delivery. The American Cancer Society projects more than 2 million new cancer cases per year in the United States, and ASCO’s 2025 State of the Hematology and Medical Oncologist Workforce report found that the density of oncologists relative to the aging population is declining. In 2014, there were an estimated 15.9 oncologists per 100,000 people aged 55 and older; that figure dropped to 14.9 by 2024. Non-metropolitan areas are projected to meet only 29% of their oncologist demand by 2037.
The challenge compounds between clinic visits. A cross-sectional study published in JAMA Network Open analyzed more than 35 million emergency department visits by cancer patients and found that 51.6% were potentially preventable. Pain was the most common driver of those visits, and the absolute number of preventable cancer-related ED visits nearly doubled between 2012 and 2019.
“Between clinic visits, patients often describe symptoms in ways that are nuanced, evolving and deeply personal. What’s powerful about this evolution of Remi is its ability to translate those real-world conversations into clinically meaningful signals for our care teams.” — Pallav Mehta, MD, Medical Director at Reimagine Care
“Between clinic visits, patients often describe symptoms in ways that are nuanced, evolving and deeply personal,” said Pallav Mehta, MD, Medical Director at Reimagine Care. “What’s powerful about this evolution of Remi is its ability to translate those real-world conversations into clinically meaningful signals for our care teams. Instead of sorting through fragmented messages, clinicians can quickly understand what’s happening with a patient and focus on making the right decision at the right time.”
Expanding Into Advanced Therapies
Among the more notable claims in this platform evolution is Reimagine Care’s positioning around CAR-T cell therapy support outside the hospital. The company says the upgraded platform opens the door to supporting patients on CAR-T and other advanced therapies in the home setting, a clinically complex use case given CAR-T’s risk profile, which includes cytokine release syndrome and neurotoxicity.
The push aligns with a growing body of clinical research into outpatient CAR-T delivery. A 2025 study published in JCO Oncology Practice examined models of care for outpatient CAR-T administration and concluded that safe delivery requires a multidisciplinary team and clinical pathways for rapid triage. Remote patient monitoring is increasingly viewed as a necessary component of that infrastructure. Whether Remi’s conversational model is sufficient to meet the monitoring demands specific to CAR-T, or whether it functions as one layer within a broader monitoring stack, is a question Reimagine Care has not yet addressed in detail.
Beyond advanced therapies, the company says the platform is intended to extend across the broader cancer journey, including survivorship and end-of-life care. According to the company, Remi has now supported more than 10,000 patients and hundreds of thousands of interactions.
Patient Expectations and the Digital Convenience Gap
CEO Dan Nardi framed the platform evolution in part around shifting patient expectations for digital responsiveness.
“Across nearly every part of daily life, people now expect services that respond immediately and interact with them in natural, conversational ways that’s in their preferred channel,” said Nardi. “If someone can get something as simple as dinner or a hair dryer delivered to their doorstep within an hour — and they can communicate with conversational AI via text for support — then healthcare should be able to offer that same level of responsiveness for something as serious as cancer. The evolution of Remi brings those expectations into oncology care, allowing patients to communicate in their own words while giving care teams the insight they need to respond earlier and more thoughtfully.”
The company’s existing deployments include a pilot program with MedStar Health and a partnership with Tampa General Hospital’s Cancer Institute, which is backed by an investment from TGH Ventures, the hospital’s venture arm.
Competitive Context
Reimagine Care operates in a market that includes a range of companies applying AI to cancer care, though most competitors are focused on different segments of the oncology workflow. Diagnostic AI companies such as Tempus AI and Lunit focus on imaging, genomics, and treatment matching. ASCO and Google collaborated in 2025 to launch an AI-powered tool to help oncologists access clinical guidelines. Clinical trial recruitment platforms like Deep 6 AI (acquired by Tempus) focus on patient matching.
Reimagine Care’s positioning is narrower and more patient-facing: it addresses the space between clinic visits, not clinical decision support at the point of care. The company’s closest competitive category is AI-powered between-visit patient engagement for oncology, an area where purpose-built platforms with oncology-specific clinical pathways, staffed Virtual Care Centers, and human escalation workflows represent a distinct model from general-purpose remote monitoring or patient portal messaging.
— This original article was created with AI support.
